Andrew Ashe - Aug 25, 2022 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
President, Chief Operating Officer and General Counsel
Signature
/s/ Andrew Ashe
Stock symbol
VERV
Transactions as of
Aug 25, 2022
Transactions value $
$152,217
Form type
4
Date filed
8/29/2022, 05:00 PM
Previous filing
Feb 15, 2022
Next filing
Feb 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERV Common Stock Options Exercise $71.2K +51.2K +29.99% $1.39* 222K Aug 25, 2022 Direct
transaction VERV Common Stock Options Exercise $49.9K +33.7K +15.21% $1.48* 256K Aug 25, 2022 Direct
transaction VERV Common Stock Options Exercise $31.1K +10.8K +4.24% $2.87* 267K Aug 25, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERV Stock Option (right to buy) Options Exercise $0 -51.2K -100% $0.00* 0 Aug 25, 2022 Common Stock 51.2K $1.39 Direct F1
transaction VERV Stock Option (right to buy) Options Exercise $0 -33.7K -55.56% $0.00 27K Aug 25, 2022 Common Stock 33.7K $1.48 Direct F2
transaction VERV Stock Option (right to buy) Options Exercise $0 -10.8K -6.6% $0.00 153K Aug 25, 2022 Common Stock 10.8K $2.87 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The remaining shares underlying this option, which was granted on November 8, 2018, were fully vested as of August 20, 2022.
F2 The remaining shares underlying this option, which was granted on September 17, 2019, vest in equal monthly installments until July 26, 2023.
F3 The remaining shares underlying this option, which was granted on September 16, 2020, vest in equal monthly installments until September 16, 2024.

Remarks:

President, Chief Operating Officer and General Counsel